Tayahop, Kianna .
HRN: 27-66-40 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/02/2025
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
10/02/2025
10/08/2025
IVTT
65mg
IVTT
Sepsis; R/o CNS Infection
Waiting Final Action
Indication: Empiric Type of Infection: Bloodstream Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes